🍽️ iopanoic acid,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Diagnostic Imaging: Iopanoic acid is administered orally to aid in the visualization of the biliary tract and gallbladder during cholecystography. It helps outline the anatomical structures of interest, allowing healthcare providers to assess the function and integrity of the gallbladder and bile ducts.

  2. Biliary Tract Imaging: Cholecystography with iopanoic acid is commonly used to diagnose various conditions affecting the biliary system, including gallstones (cholelithiasis), inflammation of the gallbladder (cholecystitis), and bile duct obstructions. By providing detailed images of the biliary anatomy, this procedure helps healthcare providers identify abnormalities and plan appropriate treatment.

  3. Adverse Reactions: Like other contrast agents, iopanoic acid may cause adverse reactions in some individuals. Common side effects may include nausea, vomiting, abdominal discomfort, diarrhea, and a temporary alteration in taste. These reactions are usually mild and self-limiting.

  4. Allergic Reactions: Allergic reactions to iopanoic acid are rare but possible. Some individuals may experience hypersensitivity reactions characterized by itching, rash, hives, or swelling. Severe allergic reactions, such as anaphylaxis, are very uncommon but can occur. Patients with a history of allergies, asthma, or previous reactions to iodinated contrast agents should inform their healthcare provider before undergoing cholecystography with iopanoic acid.

  5. Renal Effects: Unlike intravenously administered iodinated contrast agents used in procedures like CT scans, iopanoic acid, when taken orally, is not associated with the same risk of contrast-induced nephropathy (CIN), a temporary decrease in kidney function. However, caution should be exercised in patients with pre-existing kidney disease or impaired renal function.

  6. Precautions: Iopanoic acid should be used with caution in patients with known hypersensitivity to iodine-containing compounds. Additionally, it may interfere with thyroid function tests due to its iodine content, so thyroid function should be assessed appropriately before and after the procedure.

  7. Contraindications: Iopanoic acid is contraindicated in patients with known hypersensitivity to the drug or its components. It should also be avoided in patients with acute hepatitis or other acute liver diseases, as well as those with significant biliary tract obstruction.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of iopanoic acid,(prescription) On Probiotics

Rank Probiotic Impact
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces

Bacteria Impacted by iopanoic acid,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Segatella genus Decreases 👪 Source Study
Clostridium genus Decreases 👪 Source Study Pathogen
Coprococcus genus Decreases 👪 Source Study
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Agathobacter genus Decreases 👪 Source Study
Odoribacter genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Clostridioides genus Decreases 👪 Source Study
Ruminococcus genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Mediterraneibacter genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Phocaeicola genus Decreases 👪 Source Study
Phocaeicola genus Increases 👪 Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Eggerthellales order Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Coprococcus comes species Decreases 📓 Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Bilophila wadsworthia species Decreases 📓 Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Agathobacter rectalis species Decreases 📓 Source Study
Odoribacter splanchnicus species Decreases 📓 Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Clostridioides difficile species Decreases 📓 Source Study Colitis
Ruminococcus bromii species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
[Ruminococcus] gnavus species Decreases 📓 Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Allisonella histaminiformans species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Phocaeicola vulgatus species Increases 📓 Source Study
Phocaeicola vulgatus 274-1D4 strain Increases 👶 Source Study
Phocaeicola vulgatus ATCC 8482 strain Increases 👶 Source Study
Phocaeicola vulgatus CL09T03C04 strain Increases 👶 Source Study
Phocaeicola vulgatus dnLKV7 strain Increases 👶 Source Study
Phocaeicola vulgatus PC510 strain Increases 👶 Source Study
Phocaeicola vulgatus RJ2L3 strain Increases 👶 Source Study
Phocaeicola vulgatus str. 3775 SL(B) 10 (iv) strain Increases 👶 Source Study
Phocaeicola vulgatus str. 3775 SR(B) 19 strain Increases 👶 Source Study
Phocaeicola vulgatus str. 3975 RP4 strain Increases 👶 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of iopanoic acid,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.5 0.5
ADHD 2.5 0.5 4
Age-Related Macular Degeneration and Glaucoma 0.3 -0.3
Allergic Rhinitis (Hay Fever) 1.6 1.6
Allergies 1.8 2.1 -0.17
Allergy to milk products 1.4 0.4 2.5
Alopecia (Hair Loss) 0.9 0.9
Alzheimer's disease 3.8 4.8 -0.26
Amyotrophic lateral sclerosis (ALS) Motor Neuron 1.9 0.6 2.17
Ankylosing spondylitis 2.4 1.5 0.6
Anorexia Nervosa 0.3 1.6 -4.33
Antiphospholipid syndrome (APS) 1.2 0.5 1.4
Asthma 0.5 0.4 0.25
Atherosclerosis 0.8 1.3 -0.63
Atrial fibrillation 1.8 2.2 -0.22
Autism 5.9 5.4 0.09
Barrett esophagus cancer 0.5 0.5
benign prostatic hyperplasia 0.1 0.1
Biofilm 1.6 1.6
Bipolar Disorder 1.5 0.8 0.88
Brain Trauma 0.4 -0.4
Cancer (General) 0.4 1.6 -3
Carcinoma 1.9 1.3 0.46
Celiac Disease 1.1 1.9 -0.73
Cerebral Palsy 0.5 0.7 -0.4
Chronic Fatigue Syndrome 4.1 5.4 -0.32
Chronic Kidney Disease 1.1 1.3 -0.18
Chronic Lyme 0.4 -0.4
Chronic Obstructive Pulmonary Disease (COPD) 0.5 0.5 0
Chronic Urticaria (Hives) 0.9 1.9 -1.11
Coagulation / Micro clot triggering bacteria 0.7 0.3 1.33
Colorectal Cancer 4 0.4 9
Constipation 0.5 0.1 4
Coronary artery disease 1.1 0.5 1.2
COVID-19 4.5 6.5 -0.44
Crohn's Disease 6.5 4 0.63
cystic fibrosis 0.4 0.4 0
deep vein thrombosis 0.4 0.3 0.33
Depression 5.6 5 0.12
Eczema 0.5 1.4 -1.8
Endometriosis 1.5 0.7 1.14
Eosinophilic Esophagitis 0.5 0.5
Epilepsy 1.9 0.7 1.71
Fibromyalgia 0.8 3.5 -3.38
Functional constipation / chronic idiopathic constipation 2.7 3.3 -0.22
gallstone disease (gsd) 1.2 0.5 1.4
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 1.4 0.1 13
Generalized anxiety disorder 1.3 1.3 0
giant cell arteritis 0.5 -0.5
Gout 0.5 -0.5
Graves' disease 0.6 0.6
Halitosis 0.8 0.8
Hashimoto's thyroiditis 0.4 0.8 -1
Hidradenitis Suppurativa 0.9 0.9
High Histamine/low DAO 1.7 0.3 4.67
hypercholesterolemia (High Cholesterol) 0.9 0.9
hyperglycemia 0.1 0.6 -5
hypersomnia 0.5 -0.5
hypertension (High Blood Pressure 1.1 3.6 -2.27
Hypothyroidism 0.5 -0.5
Hypoxia 0.6 0.6
IgA nephropathy (IgAN) 3.5 -3.5
Inflammatory Bowel Disease 2.1 6.3 -2
Insomnia 0.4 0.4 0
Intelligence 1.7 1 0.7
Intracranial aneurysms 0.9 0.9
Irritable Bowel Syndrome 2.6 1.3 1
Liver Cirrhosis 3.4 2.1 0.62
Long COVID 4.3 4.8 -0.12
Low bone mineral density 0.5 -0.5
Lung Cancer 0.1 0.3 -2
Mast Cell Issues / mastitis 0.1 0.8 -7
ME/CFS with IBS 0.5 1.3 -1.6
ME/CFS without IBS 1 1.3 -0.3
Metabolic Syndrome 5 4.8 0.04
Mood Disorders 7.8 5 0.56
Multiple Sclerosis 1.5 6.1 -3.07
Multiple system atrophy (MSA) 0.3 -0.3
neuropathic pain 0.4 -0.4
Neuropathy (all types) 0.1 -0.1
neuropsychiatric disorders (PANDAS, PANS) 0.7 0.7
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 1.6 2.4 -0.5
Obesity 3.7 2.9 0.28
obsessive-compulsive disorder 3.9 3.1 0.26
Osteoarthritis 1.4 0.3 3.67
Osteoporosis 1.3 0.4 2.25
pancreatic cancer 0.4 0.4
Parkinson's Disease 1.5 2.7 -0.8
Polycystic ovary syndrome 1.6 1.6 0
Postural orthostatic tachycardia syndrome 0.5 0.5 0
Premenstrual dysphoric disorder 0.3 -0.3
primary biliary cholangitis 0.7 -0.7
Psoriasis 2 3 -0.5
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 4.3 3.1 0.39
Rosacea 0.3 0.5 -0.67
Schizophrenia 4.4 1.3 2.38
scoliosis 0.5 0.8 -0.6
Sjögren syndrome 1.8 1.8 0
Sleep Apnea 1.2 0.9 0.33
Slow gastric motility / Gastroparesis 1 1
Small Intestinal Bacterial Overgrowth (SIBO) 0.7 0.7
Stress / posttraumatic stress disorder 1.9 0.9 1.11
Systemic Lupus Erythematosus 3.8 0.7 4.43
Tic Disorder 0.7 1.2 -0.71
Tourette syndrome 0.4 -0.4
Type 1 Diabetes 2.8 0.6 3.67
Type 2 Diabetes 4.5 5.3 -0.18
Ulcerative colitis 1.7 4.2 -1.47
Unhealthy Ageing 4.6 1.8 1.56

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results. < p > Explanations / Info / Descriptions are influenced by < a href = "/home/sources" target = "_blank" > Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction. < p style = "font-size" .4em"> Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA < br /> Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. < br />< em > Caveat emptor: Analysis and suggestions are based on modelling(and thus < i > infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions / Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [44.213.60 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [44.213.60 ]